Amidst controversy, the FDA finally approved the controversial prostate cancer therapy. Hopes are high that Provenge represents the first in a long line of effective immunotherapeutics.
Jonathan S. Batchelor
Advertisement
Articles by Jonathan S. Batchelor
Advertisement
Latest Updated Articles
Provenge wild ride blazes trail for immunotherapyDecember 6th 2010
Advertisement
Advertisement
Trending on CancerNetwork
1
58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative
2
3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
3
57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers
4
From Conference to Practice: Top 5 Takeaways From EHA 2026
5